ArticleJAAD case reports2025

Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting.

Emma L Myers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.